Alberto Sánchez-Camacho

Dr. Alberto Sánchez-Camacho

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ASAlberto Sánchez-Camacho
Alberto Sánchez-Camacho
ATAlberto Torres-Zurita
Alberto Torres-Zurita
LGLaura Gallego-López
Laura Gallego-López
RHRocío Hernández-Pacheco
Rocío Hernández-Pacheco
SSSilvia Silva-Romeiro
Silvia Silva-Romeiro
LCLuis De la Cruz-Merino
Luis De la Cruz-Merino
Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, particularly melanoma. However, immune-related adverse events (irAEs) pose significant challenges, particularly in cases of severe toxicity syndromes. One such life-threatening irAE is the myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome, which occurs in less than 1% of patients but has in-hospital mortality rates ranging from 40 to 60%. Due to its rarity and complexity, early recognition and a multidisciplinary approach are critical to improving outcomes.Methods: We present a single-institution case series of four patients diagnosed with MMM overlap syndrome following ICI therapy. Clinical presentation, laboratory findings, imaging, and electrophysiological tests were analyzed to confirm the diagnosis. Therapeutic interventions-including corticosteroids, intravenous immunoglobulins (IVIG), plasma exchange (PLEX), tocilizumab, and rituximab- were evaluated in terms of efficacy and clinical outcomes.Results: The onset of MMM syndrome varied from 2 to 4 weeks after initiating ICI therapy. Patients presented with rapidly progressive symptoms, including ptosis, bulbar dysfunction, respiratory distress, myopathy, and cardiac conduction abnormalities. Immunosuppressive therapy with high-dose corticosteroids was initiated in all cases. Additional immunomodulatory treatments (IVIG, tocilizumab, PLEX, and rituximab) were administered based on clinical deterioration and autoimmune profile. Two patients achieved complete recovery, one remains on maintenance immunosuppression, and one died due to respiratory failure despite aggressive treatment.Conclusion: MMM overlap syndrome is a severe and often fatal irAE associated with ICI therapy. Early identification, aggressive immunosuppressive treatment, and individualized therapeutic strategies are essential to optimize patient outcomes. Further research is needed to refine diagnostic criteria, identify predictive biomarkers, and establish standardized treatment protocols.

12 December 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NADIA HINDINADIA HINDI
NADIA HINDI
IGIrene Carrasco García
Irene Carrasco García
ASAlberto Sánchez-Camacho
Alberto Sánchez-Camacho
AGAntonio Gutierrez
Antonio Gutierrez
JPJavier Peinado
Javier Peinado
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
Symptomatic control and tumoral shrinkage is an unmet need in advanced soft-tissue sarcoma (STS) patients beyond first-line. The combination of trabectedin and radiotherapy showed activity in a recently reported clinical trial in this setting. This retrospective series aims to analyze our experience with the same regimen in the real-life setting. We retrospectively reviewed advanced sarcoma patients treated with trabectedin concomitantly with radiotherapy with palliative intent. Growth-modulation index (GMI) was calculated as a surrogate of efficacy. Forty metastatic patients were analyzed. According to RECIST, there was one (2.5%) complete response, 12 (30%) partial responses, 18 (45%) disease stabilizations, and nine (22.5%) progressions. After a median follow-up of 15 months (range 2–38), median progression-free survival (PFS) and overall survival (OS) were 7.5 months (95% CI 2.8–12.2) and 23.5 months (95% CI 1.1–45.8), respectively. Median GMI was 1.42 (range 0.19–23.76), and in 16 (53%) patients, it was >1.33. In patients with GMI >1.33, median OS was significantly longer than in those with GMI 0–1.33 (median OS 52.1 months (95% CI not reached) vs. 8.9 months (95% CI 6.3–11.6), p = 0.028). The combination of trabectedin plus radiotherapy is an active therapeutic option in patients with advanced STS, especially when tumor shrinkage for symptomatic relief is needed.

29 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NADIA HINDINADIA HINDI
NADIA HINDI
IGIrene Carrasco García
Irene Carrasco García
ASAlberto Sánchez-Camacho
Alberto Sánchez-Camacho
AGAntonio Gutierrez
Antonio Gutierrez
JPJavier Peinado
Javier Peinado
Javier Martin-BrotoJavier Martin-Broto
Javier Martin-Broto
The authors noticed that content of “Conflicts of Interest” in the original version